Finance
Gilead to Acquire Tubulis GmbH for up to $5 Billion
Published by Global Banking & Finance Review®
Posted on April 7, 2026
2 min readLast updated: April 7, 2026
Add as preferred source on GoogleQuick Summary
Gilead Sciences announced on April 7, 2026, it will acquire Germany‑based Tubulis GmbH for up to $5 billion to bolster its oncology pipeline with advanced “guided missile” antibody‑drug conjugates (ADCs). The deal adds innovative ADC platforms targeting solid tumors.
Gilead to buy Germany's Tubulis for up to $5 billion to boost cancer pipeline
Gilead's Strategic Acquisition of Tubulis and Its Impact on Cancer Drug Development
Overview of the Acquisition
April 7 (Reuters) - Gilead said on Tuesday it would acquire private Germany-based Tubulis GmbH for up to $5 billion, as the U.S. drugmaker looks to boost its pipeline with a lucrative class of experimental cancer drugs referred to as "guided missiles".
This marks the latest in Gilead's acquisition spree. The company has been expanding beyond its key areas for growth amid looming patent expiries and declining sales of its COVID-19 treatment.
Recent Acquisitions by Gilead
In February, the drugmaker bought partner Arcellx for up to $7.8 billion, its biggest deal since 2020, to strengthen its lineup of cancer treatments. Last month, it agreed to acquire privately held biotech firm Ouro Medicines in a deal worth more than $2 billion to expand its pipeline of immune disorder drugs.
Details of Tubulis and Its Drug Pipeline
Antibody-Drug Conjugates: The "Guided Missiles"
With the latest deal, Gilead will get access to Tubulis' drugs, which belong to the class called antibody-drug conjugates (ADC), popularly known as "guided missiles", that deliver chemotherapy directly to cancer cells while minimizing harm to healthy tissue.
Lead Assets: TUB-040 and TUB-030
Tubulis' lead asset, TUB-040, which binds to NaPi2b, a protein found in certain cancer cells, is currently in early-stage development for a type of ovarian cancer and non-small cell lung cancer.
Another experimental drug, TUB-030, is being studied across various solid tumor types.
Significance of the Deal and Future Outlook
Statements from Gilead Leadership
"The agreement to acquire Tubulis is a significant milestone in Gilead's progress in oncology," said Gilead CEO Daniel O'Day.
Financial Terms and Partnerships
Under the terms of the deal, Gilead will acquire all of the outstanding equity of Tubulis for $3.15 billion in upfront cash, payable at closing, and up to $1.85 billion in milestone payments.
The companies have previously entered into licensing agreements to develop ADCs. Tubulis also has a partnership with Bristol-Myers Squibb
Integration and Future Operations
Following the close of the transaction, expected in the second quarter of 2026, Tubulis will operate as an ADC research organization within Gilead.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shinjini Ganguli)
Key Takeaways
- •The acquisition gives Gilead access to Tubulis’ proprietary Tubutecan and Alco5 ADC platforms, promising more stable, durable targeted cancer therapies with reduced off‑target toxicity (pharmaphorum.com).
- •Tubulis’ lead clinical asset, TUB‑040 (targeting NaPi2b in ovarian and non‑small cell lung cancer), has received FDA Fast Track designation and is in Phase I/IIa trials; TUB‑030 targeting 5T4 is also advancing (lmu.de).
- •Tubulis recently raised €308 million (~$358 million) in Series C funding to accelerate ADC clinical development—underscoring strong investor confidence and setting high strategic value for Gilead’s acquisition (pharma.economictimes.indiatimes.com)
References
Frequently Asked Questions about Gilead to acquire Tubulis GmbH for up to $5 billion
1Who is acquiring Tubulis GmbH?
Gilead is acquiring Tubulis GmbH, a Germany-based private biotech company.
2What is the value of the Gilead and Tubulis deal?
The acquisition is valued at up to $5 billion.
3What does Gilead aim to gain from the acquisition?
Gilead aims to boost its pipeline with experimental cancer drugs, described as 'guided missiles'.
4Where is Tubulis GmbH based?
Tubulis GmbH is based in Germany.
